This experiment evaluates the efficacy of [TREM2](/proteins/trem2) agonistic antibodies in mouse models of Alzheimer's disease, focusing on microglial activation, amyloid clearance, and cognitive outcomes.
Hypothesis
Primary Hypothesis: TREM2 agonist treatment will enhance microglial phagocytic activity, reduce amyloid plaque burden, and improve cognitive function in 5xFAD mice.
Secondary Hypothesis: Early intervention (pre-symptomatic) will show greater benefit than late intervention (symptomatic).
Background
[TREM2](/proteins/trem2) (Triggering Receptor Expressed on Myeloid Cells 2) is a receptor on [microglia](/cell-types/microglia-neuroinflammation) that plays a critical role in amyloid clearance. Rare variants in [TREM2](/genes/trem2) increase Alzheimer's disease risk by 3-5x. TREM2 agonism represents a promising therapeutic approach, but optimal dosing and timing remain unknown.
Key questions to address:
What is the optimal dosing regimen for TREM2 agonists?
Does timing of intervention affect outcomes?
What are the downstream effects on the [microglial landscape](/cell-types/microglia)?
This experiment evaluates the efficacy of [TREM2](/proteins/trem2) agonistic antibodies in mouse models of Alzheimer's disease, focusing on microglial activation, amyloid clearance, and cognitive outcomes.
Hypothesis
Primary Hypothesis: TREM2 agonist treatment will enhance microglial phagocytic activity, reduce amyloid plaque burden, and improve cognitive function in 5xFAD mice.
Secondary Hypothesis: Early intervention (pre-symptomatic) will show greater benefit than late intervention (symptomatic).
Background
[TREM2](/proteins/trem2) (Triggering Receptor Expressed on Myeloid Cells 2) is a receptor on [microglia](/cell-types/microglia-neuroinflammation) that plays a critical role in amyloid clearance. Rare variants in [TREM2](/genes/trem2) increase Alzheimer's disease risk by 3-5x. TREM2 agonism represents a promising therapeutic approach, but optimal dosing and timing remain unknown.
Key questions to address:
What is the optimal dosing regimen for TREM2 agonists?
Does timing of intervention affect outcomes?
What are the downstream effects on the [microglial landscape](/cell-types/microglia)?
Months 3-5: Treatment phase with longitudinal sampling
Months 6-7: Terminal endpoint and tissue processing
Months 8-9: RNA-seq, data analysis
Month 10: Manuscript preparation
Total Duration: 10 months
Expected Outcomes
Primary Endpoints
30-50% reduction in amyloid plaque burden at high dose
2-fold increase in plaque-associated microglia coverage
Dose-dependent response curve established
Secondary Endpoints
Improved spatial memory in Morris water maze
20-40% reduction in CSF Aβ42
Distinct microglial transcriptomic signature in treated vs. control
Clear benefit for early vs. late intervention
Risk Mitigation
Regular health monitoring
Pre-specified endpoints to minimize animal usage
Statistical power analysis: n=25 per group for 80% power to detect 30% effect
Scoring
| Dimension | Score (1-10) | Rationale | |-----------|--------------|-----------| | Scientific Value | 10 | Addresses fundamental mechanism of microglial function in AD | | Feasibility | 8 | Established models and antibodies available | | Novelty | 9 | First comprehensive in vivo TREM2 agonist study | | Disease Impact | 10 | Direct path to clinical translation | | Reach | 7 | Primarily AD, but implications for other neurodegenerative diseases | | Cost Efficiency | 7 | Moderate cost for comprehensive mechanistic study | | Time Efficiency | 8 | 10-month timeline | | Evidence Base | 9 | Strong genetic and preclinical data | | Addresses Uncertainty | 10 | Resolves key questions about TREM2 therapeutic potential | | Translation Potential | 10 | Direct relevance to clinical development programs |